RxDoctor Payments DataLook up a doctor →

Aaron Fieker, DO

Gastroenterology · Tulsa, OKNPI 1326268079

Payments from drug & device makers

$232,433in general payments, 2019–2025

Across 854 payments — averaging $272.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bristol Myers Squibb$218K
  • AbbVie$4K
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$2K
  • Johnson & Johnson$2K
  • Takeda Pharmaceuticals U.S.A., Inc.$1K
  • Gilead$821
  • plus $5K from 35 others

What the payments were for

  • Food & beverage$14,36399%
  • Education$1401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$232,433 in reported general payments places this provider in the 95th percentile of 133 gastroenterology providers in Oklahoma.

See all gastroenterology providers in Oklahoma

Medicare billing

Part B allowed, 2024
$149,631
Medicare patients
665
Services billed
1,159

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
StelaraUstekinumab50$1,367,560
OcalivaObeticholic Acid13$119,632
CreonLipase/Protease/Amylase34$56,046
LinzessLinaclotide65$43,384
XifaxanRifaximin14$39,371
VemlidyTenofovir Alafenamide11$14,841
Mesalamine53$12,589
Ursodiol18$5,351
Omeprazole203$4,115
Pantoprazole Sodium205$3,903
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates69$3,824
Mesalamine ErMesalamine18$3,183
Tenofovir Disoproxil Fumarate12$2,822
Budesonide DrBudesonide40$2,803
Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl197$2,745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonStelara$1,592$1,367,56050 claims
Intercept Pharmaceuticals, Inc.Ocaliva$694$119,63213 claims
AbbVieCreon, Linzess$4,136$99,43099 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$1,886$39,37114 claims
GileadVemlidy$821$14,84111 claims
Braintree Laboratories, Inc.Sutab$16$2,09613 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 133 gastroenterology providers in Oklahoma.

Other gastroenterology in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →